JKS Hepatitis Market Information Lineup - December 2004

Source   Summary   Information available from JKS
Ministry of Health, Labor and Welfare, Japan


Effective November 1, 2000 the Japanese Ministry of Health, Labor and Welfare (MHLW) created a special "Hepatitis Task Force". The prime objective of the joint task force was to generate policy and practical measures to counteract the growing number of Hepatitis B virus (HBV) and Hepatitis C virus (HCV) cases in Japan, and the highest in the world mortality rate of liver cancer. Over the past 4 years, it became clear that especially the spread of the hepatitis C virus is much wider than estimated. Most recently on December 9, 2004, the MHLW disclosed that in 1980s and 90s over 6,600 medical facilities nation-wide have administered HCV-tainted blood-derived products. The announcement of the names of the hospitals and clinics aims to prompt the former patients to undergo testing, thus revealing the real scale of the epidemics in Japan. In many parts of Western Japan the morbidity of liver cancer exceeds 40 cases per 100,000 residents, as in certain regions of Kyushu is considered as endemic disease.

 Listed below are the documents and services provided by JKS in relevance to hepatitis market in Japan. Click on the links for more details or inquire for further information.





Since 2001 JKS has focused on providing critical information on the key therapeutic markets in Japan, including hepatitis, the market of associated hepatobiliary disorders, including liver cancer, and more recently on interferons.

For further information and inquiries, send email to the Regulatory Group of JKS at regulatory(at)jouhoukoukai.com

This is a CAN-SPAM compliant service email. Jouhou Koukai Editorial office is located at Shinagawa Intercity Tower A, 28F, Konan 2-15-1, Minato-ku, Tokyo 108-6028, Japan. Send further inquiries to orders(at)jouhoukoukai.com. Copyright 2004 by Jouhou Koukai Services LLC. All rights reserved.